Traws Pharma Inc (TRAW) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
Traws Pharma Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Traws Pharma Inc 's ROA in the second quarter of 2026?
Traws Pharma Inc recorded a cumulative net loss of $-17 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -156.83%.
However, within the Healthcare sector 814 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 59 to 4343.
Traws Pharma in Transition: Charting a Course through Financial Struggles and Promising InnovationsNEWTOWN, Pa.—In a surprising move, Traws Pharma, Inc. (NASDAQ: TRAW), a clinical-stage biopharmaceutical company at the forefront of developing therapies against respiratory viral diseases, announced the retirement of its Chief Executive Officer, Dr. Werner Cautreels, effective March 31, 2025. The announcement comes on the heels of a string of mixed financial results and a significant milestone in the company’s antiviral research.Dr. Iain D. Dukes, a seasoned biopharma veteran and the current Chairman, will step in as Interim CEO during this pivotal time. While the leadership change raises eyebrows, Traws is in a unique position as it reports an interim positive development in its research pipeline. Just days before the management shake-up, the company unveiled promising results from its drug candidate, tivoxavir marboxil (TXM), which showed potential as a single-dose treatment for H5N1 avian influenza.
Traws Pharma, a rising biopharmaceutical company, has recently released encouraging Phase 1 data for its investigational antiviral drug, Tivoxavir Marboxil. The novel agent, designed for single-dose treatment or prevention of both seasonal and pandemic influenza, demonstrated efficacy and safety in early clinical trials. However, despite these promising scientific developments, the company is currently navigating significant financial challenges, as reflected in its latest financial report. Promising Phase 1 Clinical DataIn a recent announcement, Traws Pharma unveiled positive topline results from the Phase 1 trial of Tivoxavir Marboxil, positioning the drug as a potential breakthrough in influenza management. The investigational agent aims to simplify influenza treatment by offering a one-dose solution, targeting both seasonal and pandemic strains. Early data indicate that Tivoxavir Marboxil is not only safe but also demonstrates a strong antiviral response. Such findings are of particular interest in the context of ongoing global efforts to enhance preparedness against pandemics, offering a promising addition to the arsenal of influenza interventions.
Comment on TRAW's ROA in the fiscal year ending 2024
In the fiscal year 2024 ROA improved to 64.66 % compared to prior year, due to annual net income growth of % to $6.87 million, and due to decline of value in Traws Pharma Inc 's assets by -53.39 % to $10.62 million, compared to $10.62 a year before.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
